"Leading the Indian generic push into Singapore is Ranbaxy Laboratories, which first established its operations in 2001 with 14 molecules covering a wide range of therapeutic segments including anti-infective and anti-depressant. Similarly, Strides Pharma Global, a subsidiary of Strides Arcolab, obtained an 'International Headquarters Status' by the Economic Development Board in January 2015, following a decision to build a new manufacturing facility in the country and to use Singapore as a launch board into South East Asia," the firm added. How about the domestic players? They focus mainly on generic drugs and health supplement products, BMI Research said and cited privately-owned Beacons Pharmaceuticals which produces its own range of generic products as well as provides contract manufacturing and packaging services. However, they are facing growing competition from foreign generic players, which are making inroads into the government tender market.